Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
C Yan, A Richmond - Molecular Cancer, 2021 - Springer
Molecular Cancer, 2021•Springer
Highlights CD40 expression correlates with the type I anti-tumor response and better
survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11
cancer types, including RAS mut melanoma compared to nevi. RAS mutation correlates with
reduced CD40 expression in malignant melanoma. CD40 expression is associated with
better response to immune checkpoint blockade therapy in melanoma.
survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11
cancer types, including RAS mut melanoma compared to nevi. RAS mutation correlates with
reduced CD40 expression in malignant melanoma. CD40 expression is associated with
better response to immune checkpoint blockade therapy in melanoma.
Highlights
- CD40 expression correlates with the type I anti-tumor response and better survival.
- Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RASmut melanoma compared to nevi.
- RAS mutation correlates with reduced CD40 expression in malignant melanoma.
- CD40 expression is associated with better response to immune checkpoint blockade therapy in melanoma.
Springer
